The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Outcomes of alloSCT with PTCy-based GvHD prophylaxis in elderly patients with acute leukemia or MDS
Muhammad Umair Mushtaq, MD, University of Kansas Medical Center, Kansas City, KS, discusses a study investigating outcomes of allogeneic stem cell transplantation (alloSCT) with post-transplant cyclophosphamide(PTCy)-based graft-versus-host disease (GvHD) prophylaxis in elderly patients with acute leukemia or myelodysplastic syndromes (MDS). Dr Mushtaq notes that with careful patient selection, outcomes can be similar to those of younger patients. The only significant association was a higher risk of non-relapse mortality in elderly patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We retrospectively reviewed the registry database maintained by CIBMTR. We looked at 865 patients who received a matched sibling donor or haploidentical allogenic hematopoietic stem cell transplant with post-transplant cyclophosphamide-based GVHD prophylaxis. And these patients had acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes. And we wanted to look at the outcomes of patients who are elderly, over the age of 70...
We retrospectively reviewed the registry database maintained by CIBMTR. We looked at 865 patients who received a matched sibling donor or haploidentical allogenic hematopoietic stem cell transplant with post-transplant cyclophosphamide-based GVHD prophylaxis. And these patients had acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes. And we wanted to look at the outcomes of patients who are elderly, over the age of 70. Although we numerically found lower survival and disease-free survival in these patients, but in the adjusted multivariate analysis, the age was not significantly associated with overall survival, disease-free survival, relapse, acute and chronic graft-versus-host disease. The only factor it was associated with was a relatively higher risk of non-relapse mortality. So with careful patient selection, similar outcomes can be achieved in elderly patients using post-transplant cyclophosphamide-based GVHD prophylaxis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Iovance Biotherapeutics: Research Funding.
